There were 1,621 press releases posted in the last 24 hours and 442,733 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image